FĂ©licitations Ă nos chercheurs et Ă nos chercheurs-cliniciens
pour leurs publications !
Dre Isabelle Fleury
Stewart DA, Kuruvilla J, Lee D, Dudebout JJ, Chua N, Larouche JF, Baetz T, Shafey M, Abdel-Samad N, Robinson S, Fleury I, Fraser G, Skrabek P, Kukreti V, Kelly J, Hay AE, Shepherd LE, Chen BE, Crump M. Canadian cancer trials group LY.17: A randomized phase II study evaluating novel salvage therapy pre-autologous stem cell transplant in relapsed/refractory diffuse large B-cell lymphoma-outcome of rituximab-dose-intensive cyclophosphamide, etoposide, cisplatin (R-DICEP) versus R-GDP. Br J Haematol. 2024 Sep;205(3):881-890. doi: 10.1111/bjh.19555. Epub 2024 May 27. PMID: 38802107.
Drs Josée Hébert et Guy Sauvageau
Grenier JMP, Testut C, Bal M, Bardin F, De Grandis M, Gelsi-Boyer V, Vernerey J, Delahaye M, Granjeaud S, Zemmour C, Spinella JF, Chavakis T, Mancini SJC, Boher JM, HĂ©bert J, Sauvageau G, Vey N, Schwaller J, Hospital MA, Fauriat C, Aurrand-Lions M. Genetic deletion of JAM-C in preleukemic cells rewires leukemic stem cell gene expression program in AML. Blood Adv. 2024 Sep 10;8(17):4662-4678. doi: 10.1182/bloodadvances.2023011747. PMID: 38954834.
Safa-Tahar-Henni S, Páez Martinez K, Gress V, Esparza N, Roques E, Bonnet-Magnaval F, Bilodeau M, Gagné V, Bresson E, Cardin S, El-Hachem N, Iasenza I, Alzial G, Boivin I, Nakamichi N, Soufflet AC, Pascariu CM, Duchaine J, Mathien S, Bonneil E, Eppert K, Marinier A, Sauvageau G, Deblois G, Thibault P, Hébert J, Eaves CJ, Cellot S, Barabé F, Wilhelm BT. Comparative small molecule screening of primary human acute leukemias, engineered human leukemia and leukemia cell lines. Leukemia. 2024 Oct 29. doi: 10.1038/s41375-024-02400-w. Online ahead of print. PMID: 39472547.
Pr Chris E Rudd
Ben Saad E, Oroya A, Anto NP, Bachais M, Rudd C. PD-1 endocytosis unleashes the cytolytic potential of checkpoint blockade in tumor immunity. Cell Rep. 2024 Oct 28;43(11):114907. doi: 10.1016/j.celrep.2024.114907. Online ahead of print. PMID: 39471174.
Dre Natasha Szuber
L’article a aussi été mentionné dans la revue de l’ASH !
Szuber N, Olney HJ, Dagenais-Bellefeuille S, Tanguay M, Shehabeldeen A, Ahmed S, Harnois M, Prchal J, Busque L, Sirhan S. Perioperative outcomes in patients with myeloproliferative neoplasms: a multicentric analysis of 354 surgical procedures. Blood Vessels, Thrombosis & Hemostasis, Volume 1, Issue 4, 2024, Doi: 10.1016/j.bvth.2024.100026.
Dr Richard LeBlanc
Khan S, Bergstrom DJ, Côté J, Kotb R, LeBlanc R, Louzada ML, Mian HS, Othman I, Visram A. First Line Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma: Recommendations from a Canadian Consensus Guideline Consortium. Accepté pour publication dans Clin Lymphoma Myeloma Leuk.
Drs Richard LeBlanc et Jean Roy
Tanguay T, Roy J, Su J, Gul E, Reece D, Venner CP, White D, Chu MP, Umenez- Zepada VH, Song K, Mccurdy A, Mian H, Sebag M, Bergstrom D, Stakiw J, Reiman A, Kotb R, Aslam M, Kaedbey R, Louzada M, LeBlanc R. Disease Characteristics and Outcomes of 493 Young Myeloma Patients Treated with Modern Therapies: A CMRG database study. Accepté pour publication dans Cancer Med.
Plusieurs membres comme auteurs
Terra R, Éthier V, Busque L, Morin-Quintal A, D’Angelo G, Hébert J, Wang X, LeBlanc R, Bergeron J. Improved identification of clinically relevant Acute Leukemia subtypes using standardized EuroFlow panels versus non-standardized approach. Accepté pour publication dans Cytometry Part B: Clinical Cytometry.
LeBlanc R, Thiant S, Terra R, Ahmad I, Claveau JS, Bambace N, Bernard L, Cohen S, Delisle JS, Lachance S, Kiss T, Roy DC, Sauvageau G, and Roy J. A phase II, open-label study of Lenalidomide and Dexamethasone followed by donor lymphocyte infusions in relapsed multiple myeloma following upfront allogeneic stem cell transplant. Accepté dans Current Oncology.